Clinical trial
Clinical Trial of Lurbinectedin as Single-agent or in Combination With…
NCT05153239 · PharmaMar, Industry · Active, not recruiting
Key facts
| NCT number | NCT05153239 |
|---|---|
| Title | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) |
| Official title | A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial) |
| Lead sponsor | PharmaMar, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsed Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Irinotecan, Lurbinectedin, Topotecan |
| Enrollment | 705 |
| Start date | Jul 22, 2022 |
| Primary completion | Apr 1, 2026 |
| Completion | Apr 1, 2026 |
| First posted | Dec 10, 2021 |
| Last update posted | Feb 10, 2026 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Denmark, France, Georgia, Germany, Hungary and 12 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: